Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24037600 | 0.84 | AXL (0.57) | KDR | |
| SCHEMBL29834707 | 0.84 | ABL1 (0.51) | KDRFLT1CYP17A1MAPK14MAPK13 | |
| SCHEMBL16895218 | 0.84 | MAPK14 (0.53) | KDRFLT1CYP17A1MAPK14MAPK13 | |
| SCHEMBL30729902 | 0.84 | MAPK14 (0.53) | KDRFLT1CYP17A1MAPK14MAPK13 | |
| SCHEMBL29834768 | 0.83 | KDR (0.45) | KDRFLT1CYP17A1MAPK14MAPK13 | |
| SCHEMBL2858354 | 0.83 | MAPK14 (0.63) | KDRFLT1CYP17A1MAPK14MAPK13 | |
| SCHEMBL24037398 | 0.83 | MAPK14 (0.48) | KDRFLT1CYP17A1MAPK14MAPK13 | |
| SCHEMBL30729886 | 0.82 | KDR (0.46) | KDRFLT1CYP17A1MAPK14MAPK13 | |
| SCHEMBL29834639 | 0.81 | ABL1 (0.50) | KDRFLT1CYP17A1MAPK14MAPK13 | |
| SCHEMBL30729882 | 0.81 | MAPK14 (0.46) | KDRFLT1CYP17A1MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2022170043-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ERBB2, EGFR, ERBB4 | KDR 48/4885FLT1 212/4885CYP17A1 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.